Results 91 to 100 of about 150,694 (118)

Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis. [PDF]

BMC Cancer
de Moraes FCA, de Almeida Barbosa AB, Sano VKT, Kelly FA, Burbano RMR.   +4 more
europepmc   +1 more source

Management of patients with reduced dihydropyrimidine dehydrogenase activity receiving combined 5-fluoruracil-/capecitabine-based chemoradiotherapy. [PDF]

Strahlenther Onkol
Hoffmann E, Toepell A, Peter A, Böke S, De-Colle C, Steinle M, Niyazi M, Gani C.   +7 more
europepmc   +1 more source

The Path to Clinical Implementation of <italic>DPYD</italic> Pharmacogenetic Testing: Long-Term Experience from an External Quality Assessment Provider and a University Testing Center.

Oncol Res Treat
Hedtke M, Ast V, Leidheiser J, Kessler A, Neumaier M, Hofheinz RD, Haselmann V.   +6 more
europepmc   +1 more source

Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study. [PDF]

Cancer Med
De Metz C, Hennart B, Aymes E, Cren PY, Martignène N, Penel N, Barthoulot M, Carnot A.   +7 more
europepmc   +1 more source

Dihydropyrimidine Dehydrogenase Deficiency (DPYD) Genotyping-Guided Fluoropyrimidine-Based Adjuvant Chemotherapy for Breast Cancer. A Cost-Effectiveness Analysis. [PDF]

Clin Drug Investig
Abushanab D, Mohamed S, Abdel-Latif R, Moustafa DA, Marridi W, Elazzazy S, Badji R, Al-Muftah W, Ismail SI, Bujassoum S, Al-Thani A, Al-Badriyeh D, Al Hail M.   +12 more
europepmc   +1 more source

Clinical Implementation of Rare and Novel <i>DPYD</i> Variants for Personalizing Fluoropyrimidine Treatment: Challenges and Opportunities. [PDF]

Int J Biol Sci
De Mattia E, Milan N, Assaraf YG, Toffoli G, Cecchin E.   +4 more
europepmc   +1 more source

Severe fluoropyrimidine toxicity in older adults with cancer with DPYD wild type. [PDF]

Fundam Clin Pharmacol
Brokaar E, Knikman J, Visser L, van den Bos F, Henricks L, Lunenburg C, de Man F, Gelderblom H, Schellens J, Mathijssen R, Guchelaar HJ, Portielje J, Cats A, Postmus W, de Glas N.   +14 more
europepmc   +1 more source

Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial.

JAMA Netw Open
Roncato R, Bignucolo A, Peruzzi E, Montico M, De Mattia E, Foltran L, Guardascione M, D'Andrea M, Favaretto A, Puglisi F, Swen JJ, Guchelaar HJ, Toffoli G, Cecchin E.   +13 more
europepmc   +1 more source

Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers [PDF]

British Journal of Clinical Pharmacology, 2018
Aims: This study aimed to determine the effect of food intake on uracil and dihydrouracil plasma levels. These levels are a promising marker for dihydropyrimidine dehydrogenase activity and for individualizing fluoropyrimidine anticancer therapy. Methods:
Jan H M Schellens, Henk-Jan Guchelaar, Linda M Henricks   +2 more
exaly   +5 more sources

Nadp+-dependent formate dehydrogenase: a review

Biocatalysis and Biotransformation, 2021
Barış Binay, Saadet Alpdagtas
exaly